000520 — Samil Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩224bn
- KR₩382bn
- KR₩220bn
- 14
- 33
- 35
- 13
Annual balance sheet for Samil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 17,214 | 15,261 | 1,966 | 929 | 5,141 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 30,195 | 31,374 | 34,304 | 35,900 | 35,779 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 72,523 | 76,711 | 74,781 | 81,115 | 91,346 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 64,808 | 103,394 | 233,946 | 242,198 | 252,893 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 191,661 | 226,405 | 356,700 | 370,680 | 395,071 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 98,684 | 121,674 | 132,592 | 168,675 | 106,660 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 128,110 | 160,658 | 230,881 | 242,853 | 218,947 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 63,551 | 65,746 | 125,820 | 127,827 | 176,124 |
| Total Liabilities & Shareholders' Equity | 191,661 | 226,405 | 356,700 | 370,680 | 395,071 |
| Total Common Shares Outstanding |